Most cited papers from Immune Biosolutions (Canada)

The most cited paper from Immune Biosolutions (Canada) is "Safety and efficacy of inhaled IBIO123 for mild-to-moderate COVID-19: a randomised, double-blind, dose-ascending, placebo-controlled, phase 1/2 trial" (Bruno Maranda, Sébastien M. Labbé, Magali Lurquin et al., 2023), with 17 citations. Next come "Structure-based design of macrocyclic peptides to generate functional antibodies against G protein-coupled receptors" (1) and "A Randomized, Double-Blind, Dose-Ascending, Placebo-Controlled Phase 1-2 Trial of Inhaled IBIO123: A Monoclonal Antibodies Cocktail Treatment for Mild-To Moderate COVID-19 Illness" (1).

Showing 4 of 4 papers. Every paper is listed.

Citations are OpenAlex's own counts, from its 2026-09-23 snapshot, so the ranking can differ from Google Scholar or Web of Science. A paper is listed for an institution when any of its authors gave it as an affiliation; retracted papers and papers whose citation count cannot be traced to citing works are left out, and a preprint and the article it became are shown once. Release dates are OpenAlex's: where a source gave only a month or a year, that is what is shown. How the lists are chosen.